The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro.
Open accessAbstract
A murine hybridoma has been obtained that produces a monoclonal antibody against the human transferrin receptor. In contrast to previously characterized monoclonal antibodies that recognize the transferrin receptor, this antibody, designated 42/6, blocks the binding of transferrin to its receptor and inhibits the growth of the human T leukemic cell line, CCRF-CEM, in vitro. Inhibition of cell growth was dose dependent, and as little as 2.5 micrograms of purified antibody per ml had a detectable effect, even though transferrin was present in the tissue culture medium in large molar excess. Cells grown in the presence of antibody for 7 days accumulated in S phase of the cell cycle. The addition of iron to antibody-treated cultures in the form of ferric complexes or ferrous sulfate did not overcome the growth inhibitory effects of the anti-transferrin-receptor antibodies. This result suggests that either transferrin is the only means by which CCRF-CEM leukemic cells can be provided with sufficient iron in vitro or that other factors in addition to iron starvation are involved in the antibody-mediated growth inhibition. The inhibition of cell growth by 42/6 monoclonal antibody suggests that monoclonal antibodies against proliferation-associated cell surface antigens, such as the transferrin receptor, may be useful pharmacological reagents to modify cell growth in vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia
Foley, G. E., Lazarus, H., Farber, S., Uzman, B. G., Boone, B. A., & McCarthy, R. E. (1965) · Cancer · doi:10.1002/1097-0142(196504)18:4<522::aid-cncr2820180418>3.0.co;2-j · Cited by 1,171
Iron Transport and Storage Proteins
Aisen, P., & Listowsky, I. (1980) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.49.070180.002041 · Cited by 1,171
Methods for growth of cultured cells in serum-free medium
Barnes, D., & Sato, G. (1980) · Analytical Biochemistry · doi:10.1016/0003-2697(80)90151-7 · Cited by 1,002
Sutherland, R., Delia, D., Schneider, C., Newman, R., Kemshead, J., & Greaves, M. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.7.4515 · Cited by 685
Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin.
Trowbridge, I. S., & Omary, M. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.5.3039 · Cited by 680
Self-citationIscove, N. N., & Melchers, F. (1978) · The Journal of experimental medicine · doi:10.1084/jem.147.3.923 · Cited by 531
Nadler, L. M., Stashenko, P., Hardy, R., Kaplan, W. D., Button, L. N., Kufe, D. W., Antman, K. H., & Schlossman, S. F. (1980) · PubMed · Cited by 413
Modulation of cell surface iron transferrin receptors by cellular density and state of activation
Larrick, J. W., & Cresswell, P. (1979) · Journal of Supramolecular Structure · doi:10.1002/jss.400110415 · Cited by 357
Transferrin and transferrin receptors in carcinoma of the breast
Page Faulk, W., Hsi, B.-L., & Stevens, P. J. (1980) · The Lancet · doi:10.1016/s0140-6736(80)90440-7 · Cited by 280
Cited by
Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Jakowlew, S., Alvarez-Mon, M., Derynck, R., Sporn, M. B., & Fauci, A. S. (1986) · The Journal of experimental medicine · doi:10.1084/jem.163.5.1037 · Cited by 1,582
Daniels, T. R., Delgado, T., Rodriguez, J. A., Helguera, G., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.010 · Cited by 634
Neckers, L. M., & Cossman, J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.11.3494 · Cited by 447
Torti, S. V., Manz, D. H., Paul, B. T., Blanchette-Farra, N., & Torti, F. M. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082117-051732 · Cited by 426
de Jong, G., van Dijk, J. P., & van Eijk, H. G. (1990) · Clinica Chimica Acta · doi:10.1016/0009-8981(90)90278-z · Cited by 368
Molecular structure of serum transferrin at 3.3-.ANG. resolution
Bailey, S., Evans, R. W., Garratt, R. C., Gorinsky, B., Hasnain, S., Horsburgh, C., Jhoti, H., Lindley, P. F., & Mydin, A. (1988) · Biochemistry · doi:10.1021/bi00415a061 · Cited by 365
McClelland, A., Kühn, L. C., & Ruddle, F. H. (1984) · Cell · doi:10.1016/0092-8674(84)90004-7 · Cited by 339
Wang, J., Tian, S., Petros, R. A., Napier, M. E., & DeSimone, J. M. (2010) · Journal of the American Chemical Society · doi:10.1021/ja1043177 · Cited by 330
Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content.
Cotner, T., Williams, J. M., Christenson, L., Shapiro, H. M., Strom, T. B., & Strominger, J. (1983) · The Journal of experimental medicine · doi:10.1084/jem.157.2.461 · Cited by 318
Kurki, P., Ogata, K., & Tan, E. M. (1988) · Journal of Immunological Methods · doi:10.1016/0022-1759(88)90441-3 · Cited by 315
Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy
Tortorella, S., & Karagiannis, T. C. (2014) · The Journal of Membrane Biology · doi:10.1007/s00232-014-9637-0 · Cited by 312
Iron as a central player and promising target in cancer progression
Jung, M., Mertens, C., Tomat, E., & Brüne, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020273 · Cited by 268
Cebrián, M., Yagüe, E., Rincón, M., López-Botet, M., de Landázuri, M. O., & Sánchez-Madrid, F. (1988) · The Journal of experimental medicine · doi:10.1084/jem.168.5.1621 · Cited by 277
Miskimins, W. K., Roberts, M. P., McClelland, A., & Ruddle, F. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.20.6741 · Cited by 277
Wagner, E., Curiel, D., & Cotten, M. (1994) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(94)90008-6 · Cited by 275
Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents
Candelaria, P. V., Leoh, L. S., Penichet, M. L., & Daniels-Wells, T. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.607692 · Cited by 268
Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents
Richardson, D. R., Kalinowski, D. S., Lau, S., Jansson, P. J., & Lovejoy, D. B. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.04.003 · Cited by 258
The iron metabolism of neoplastic cells: Alterations that facilitate proliferation?
Kwok, J. C., & Richardson, D. R. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00213-x · Cited by 215
Torti, S. V., & Torti, F. M. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100860 · Cited by 153
Moura, I. C. (2004) · Blood · doi:10.1182/blood-2003-07-2440 · Cited by 114
Iron regulates T-lymphocyte sensitivity to the IFN-γ/STAT1 signaling pathway in vitro and in vivo
Regis, G., Bosticardo, M., Conti, L., De Angelis, S., Boselli, D., Tomaino, B., Bernabei, P., Giovarelli, M., & Novelli, F. (2005) · Blood · doi:10.1182/blood-2004-07-2686 · Cited by 50
Therapeutic Potential of Iron Chelators in Cancer Therapy
Richardson, D. R. (2002) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-0593-8_12 · Cited by 40
Detection of early prognostic biomarkers for metastasis of Ewing's sarcoma in pediatric patients
Ezzeldin, S., Osama, A., Anwar, A. M., Mahgoub, S., Ahmed, E. A., Farid, N., Zamzam, M., El Ghoneimy, A., & Magdeldin, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122237 · Cited by 12
Metadata
- Authors
- Trowbridge, I. S., & Lopez, F.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1982-02
- Volume
- 79
- Issue
- 4
- Pages
- 1175-1179
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1982129404
- Cited by
- 328
- References
- 28
- FWCI
- 19.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.